Ann E Woolley1, Steve K Singh1, Hilary J Goldberg1, Hari R Mallidi1, Michael M Givertz1, Mandeep R Mehra1, Antonio Coppolino1, Amanda E Kusztos1, Megan E Johnson1, Kaiwen Chen1, Esther A Haddad1, John Fanikos1, David P Harrington1, Phillip C Camp1, Lindsey R Baden1. 1. From the Divisions of Infectious Diseases (A.E.W., A.E.K., M.E.J., K.C., E.A.H., L.R.B.), Cardiac Surgery (S.K.S., H.R.M.), Thoracic Surgery (S.K.S., H.R.M., A.C., P.C.C.), Pulmonary and Critical Care Medicine (H.J.G.), and Cardiovascular Medicine (M.M.G., M.R.M.), and the Department of Pharmacy (J.F.), Brigham and Women's Hospital, Harvard Medical School (A.E.W., S.K.S., H.J.G., H.R.M., M.M.G., M.R.M., A.C., E.A.H., P.C.C., L.R.B.), Massachusetts College of Pharmacy and Health Sciences (J.F.), the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute (D.P.H.), and Harvard T.H. Chan School of Public Health (D.P.H.) - all in Boston.
Abstract
BACKGROUND: Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibility of substantially increasing the donor organ pool by enabling the transplantation of hearts and lungs from HCV-infected donors into recipients who do not have HCV infection. METHODS: We conducted a trial involving transplantation of hearts and lungs from donors who had hepatitis C viremia, irrespective of HCV genotype, to adults without HCV infection. Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regimen, was preemptively administered to the organ recipients for 4 weeks, beginning within a few hours after transplantation, to block viral replication. The primary outcome was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival at 6 months after transplantation. RESULTS: A total of 44 patients were enrolled: 36 received lung transplants and 8 received heart transplants. The median viral load in the HCV-infected donors was 890,000 IU per milliliter (interquartile range, 276,000 to 4.63 million). The HCV genotypes were genotype 1 (in 61% of the donors), genotype 2 (in 17%), genotype 3 (in 17%), and indeterminate (in 5%). A total of 42 of 44 recipients (95%) had a detectable hepatitis C viral load immediately after transplantation, with a median of 1800 IU per milliliter (interquartile range, 800 to 6180). Of the first 35 patients enrolled who had completed 6 months of follow-up, all 35 patients (100%; exact 95% confidence interval, 90 to 100) were alive and had excellent graft function and an undetectable hepatitis C viral load at 6 months after transplantation; the viral load became undetectable by approximately 2 weeks after transplantation, and it subsequently remained undetectable in all patients. No treatment-related serious adverse events were identified. More cases of acute cellular rejection for which treatment was indicated occurred in the HCV-infected lung-transplant recipients than in a cohort of patients who received lung transplants from donors who did not have HCV infection. This difference was not significant after adjustment for possible confounders. CONCLUSIONS: In patients without HCV infection who received a heart or lung transplant from donors with hepatitis C viremia, treatment with an antiviral regimen for 4 weeks, initiated within a few hours after transplantation, prevented the establishment of HCV infection. (Funded by the Mendez National Institute of Transplantation Foundation and others; DONATE HCV ClinicalTrials.gov number, NCT03086044.).
BACKGROUND: Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibility of substantially increasing the donor organ pool by enabling the transplantation of hearts and lungs from HCV-infected donors into recipients who do not have HCV infection. METHODS: We conducted a trial involving transplantation of hearts and lungs from donors who had hepatitis C viremia, irrespective of HCV genotype, to adults without HCV infection. Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regimen, was preemptively administered to the organ recipients for 4 weeks, beginning within a few hours after transplantation, to block viral replication. The primary outcome was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival at 6 months after transplantation. RESULTS: A total of 44 patients were enrolled: 36 received lung transplants and 8 received heart transplants. The median viral load in the HCV-infected donors was 890,000 IU per milliliter (interquartile range, 276,000 to 4.63 million). The HCV genotypes were genotype 1 (in 61% of the donors), genotype 2 (in 17%), genotype 3 (in 17%), and indeterminate (in 5%). A total of 42 of 44 recipients (95%) had a detectable hepatitis C viral load immediately after transplantation, with a median of 1800 IU per milliliter (interquartile range, 800 to 6180). Of the first 35 patients enrolled who had completed 6 months of follow-up, all 35 patients (100%; exact 95% confidence interval, 90 to 100) were alive and had excellent graft function and an undetectable hepatitis C viral load at 6 months after transplantation; the viral load became undetectable by approximately 2 weeks after transplantation, and it subsequently remained undetectable in all patients. No treatment-related serious adverse events were identified. More cases of acute cellular rejection for which treatment was indicated occurred in the HCV-infected lung-transplant recipients than in a cohort of patients who received lung transplants from donors who did not have HCV infection. This difference was not significant after adjustment for possible confounders. CONCLUSIONS: In patients without HCV infection who received a heart or lung transplant from donors with hepatitis C viremia, treatment with an antiviral regimen for 4 weeks, initiated within a few hours after transplantation, prevented the establishment of HCV infection. (Funded by the Mendez National Institute of Transplantation Foundation and others; DONATE HCV ClinicalTrials.gov number, NCT03086044.).
Authors: Jordan J Feld; Marcelo Cypel; Deepali Kumar; Harel Dahari; Rafaela Vanin Pinto Ribeiro; Nikki Marks; Nellie Kamkar; Ilona Bahinskaya; Fernanda Q Onofrio; Mohamed A Zahoor; Orlando Cerrochi; Kathryn Tinckam; S Joseph Kim; Jeffrey Schiff; Trevor W Reichman; Michael McDonald; Carolina Alba; Thomas K Waddell; Gonzalo Sapisochin; Markus Selzner; Shaf Keshavjee; Harry L A Janssen; Bettina E Hansen; Lianne G Singer; Atul Humar Journal: Lancet Gastroenterol Hepatol Date: 2020-05-06
Authors: Vishnu S Potluri; David S Goldberg; Sumit Mohan; Roy D Bloom; Deirdre Sawinski; Peter L Abt; Emily A Blumberg; Chirag R Parikh; James Sharpe; K Rajender Reddy; Miklos Z Molnar; Meghan Sise; Peter P Reese Journal: J Am Soc Nephrol Date: 2019-09-12 Impact factor: 10.121
Authors: Emily Bethea; Ashwini Arvind; Jenna Gustafson; Karin Andersson; Daniel Pratt; Irun Bhan; Michael Thiim; Kathleen Corey; Patricia Bloom; Jim Markmann; Heidi Yeh; Nahel Elias; Shoko Kimura; Leigh Anne Dageforde; Alex Cuenca; Tatsuo Kawai; Kassem Safa; Winfred Williams; Hannah Gilligan; Meghan Sise; Jay Fishman; Camille Kotton; Arthur Kim; Christin C Rogers; Sarah Shao; Mariesa Cote; Linda Irwin; Paul Myoung; Raymond T Chung Journal: Am J Transplant Date: 2020-02-03 Impact factor: 8.086
Authors: Jonathan Elmer; Bradley J Molyneaux; Kurt Shutterly; Susan A Stuart; Clifton W Callaway; Joseph M Darby; Amy R Weisgerber Journal: Resuscitation Date: 2019-10-22 Impact factor: 5.262